Interdisciplinary consensus on indications for transfemoral transcatheter aortic valve implantation (TF-TAVI) : Joint Consensus Document of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte e.V. (ALKK) and cooperating Cardiac Surgery Departments.
Consensus
Indication
Low risk
SAVR
TAVI
TAVR
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
04
06
2019
accepted:
03
07
2019
pubmed:
15
8
2019
medline:
23
10
2020
entrez:
15
8
2019
Statut:
ppublish
Résumé
Indications for TF-TAVI (transfemoral transcatheter aortic valve implantation) are rapidly changing according to increasing evidence from randomized controlled trials. Present trials document the non-inferiority or even superiority of TF-TAVI in intermediate-risk patients (STS-Score 4-8%) as well as in low-risk patients (STS-Score < 4%). However, risk scores exhibit limitations and, as a single criterion, are unable to establish an appropriate indication of TF-TAVI vs transapical TAVI vs SAVR (surgical aortic valve replacement). The ESC (European Society of Cardiology)/EACTS (European Association for Cardio-Thoracic Surgery) guidelines 2017 and the German DGK (Deutsche Gesellschaft für Kardiologie)/DGTHG (Deutsche Gesellschaft für Thorax-, Herz- und Gefäßchirurgie) commentary 2018 offer a framework for the selection of the best therapeutic method, but the individual decision is left to the discretion of the heart teams. An interdisciplinary TAVI consensus group of interventional cardiologists of the ALKK (Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte e.V.) and cardiac surgeons has developed a detailed consensus on the indications for TF-TAVI to provide an up-to-date, evidence-based, comprehensive decision matrix for daily practice. The matrix of indication criteria includes age, risk scores, contraindications against SAVR (e.g., porcelain aorta), cardiovascular criteria pro TAVI, additional criteria pro TAVI (e.g., frailty, comorbidities, organ dysfunction), contraindications against TAVI (e.g., endocarditis) and cardiovascular criteria pro SAVR (e.g., bicuspid valve anatomy). This interdisciplinary consensus may provide orientation to heart teams for individual TAVI-indication decisions. Future adaptations according to evolving medical evidence are to be expected. Interdisciplinary consensus on indications for transfemoral transcatheter aortic valve implantation (TF-TAVI).
Identifiants
pubmed: 31410547
doi: 10.1007/s00392-019-01528-5
pii: 10.1007/s00392-019-01528-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-12Références
Eur Heart J. 2017 Apr 21;38(16):1177-1181
pubmed: 28934845
J Am Coll Cardiol. 2019 Feb 12;73(5):537-545
pubmed: 30732706
J Am Coll Cardiol. 2017 Mar 14;69(10):1215-1230
pubmed: 27956264
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
J Am Coll Cardiol. 2017 May 9;69(18):2253-2262
pubmed: 28473128
Eur Heart J. 2016 Jul 21;37(28):2217-25
pubmed: 26819226
JACC Cardiovasc Interv. 2019 May 27;12(10):901-907
pubmed: 30860059
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
J Am Coll Cardiol. 2015 May 26;65(20):2173-80
pubmed: 25787198
J Am Coll Cardiol. 2017 Aug 8;70(6):689-700
pubmed: 28693934
J Am Coll Cardiol. 2017 Nov 14;70(20):2566-2598
pubmed: 29054308
N Engl J Med. 2010 Oct 21;363(17):1597-607
pubmed: 20961243
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
Lancet. 2016 May 28;387(10034):2218-25
pubmed: 27053442
JACC Cardiovasc Interv. 2016 Apr 25;9(8):817-824
pubmed: 27101906
N Engl J Med. 2019 May 2;380(18):1769-1770
pubmed: 31042831
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
J Am Coll Cardiol. 2018 Oct 30;72(18):2095-2105
pubmed: 30170075
N Engl J Med. 2014 May 8;370(19):1790-8
pubmed: 24678937
Lancet. 2015 Jun 20;385(9986):2477-84
pubmed: 25788234
Lancet. 2015 Jun 20;385(9986):2485-91
pubmed: 25788231
J Am Coll Cardiol. 2017 Mar 14;69(10):1313-1346
pubmed: 28063810
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Eur Heart J. 2018 Feb 21;39(8):667-675
pubmed: 29228149
J Thorac Cardiovasc Surg. 2017 Jul;154(1):7-21
pubmed: 28633212
Eur Heart J. 2014 Jun 21;35(24):1588-98
pubmed: 24022003
EuroIntervention. 2018 Jun 08;14(3):e264-e271
pubmed: 29599103
J Am Coll Cardiol. 2014 Dec 9;64(22):2340-2
pubmed: 25465420
N Engl J Med. 2012 May 3;366(18):1686-95
pubmed: 22443479
J Am Coll Cardiol. 2016 Mar 29;67(12):1472-1487
pubmed: 27012409
JACC Cardiovasc Interv. 2016 Apr 25;9(8):825-827
pubmed: 27101907
Eur Heart J. 2012 Oct;33(19):2451-96
pubmed: 22922415
N Engl J Med. 2017 Apr 6;376(14):1321-1331
pubmed: 28304219
J Am Coll Cardiol. 2019 Feb 12;73(5):554-558
pubmed: 30732708
J Am Coll Cardiol. 2019 Feb 12;73(5):546-553
pubmed: 30732707
J Am Coll Cardiol. 2016 Jun 7;67(22):2565-74
pubmed: 27050187
Eur Heart J. 2017 Jul 21;38(28):2177-2183
pubmed: 28838053
Eur J Cardiothorac Surg. 2013 May;43(5):971-7
pubmed: 23477927
Eur Heart J. 2019 Oct 7;40(38):3143-3153
pubmed: 31329852
JACC Cardiovasc Interv. 2017 May 22;10(10):1034-1044
pubmed: 28521921
Circulation. 2017 Jun 20;135(25):e1159-e1195
pubmed: 28298458
Eur Heart J. 2017 Dec 1;38(45):3382-3390
pubmed: 29020344
J Am Coll Cardiol. 2014 Dec 9;64(22):2330-9
pubmed: 25465419
Eur Heart J. 2012 Apr;33(7):822-8, 828a, 828b
pubmed: 21406443
J Am Coll Cardiol. 2017 May 9;69(18):2263-2265
pubmed: 28473129
J Clin Epidemiol. 2014 Mar;67(3):254-66
pubmed: 24472295
Circulation. 2019 Feb 1;:
pubmed: 30704298
JACC Cardiovasc Interv. 2015 Jul;8(8):1084-1091
pubmed: 26117458